How can we leverage innate "trained' immunity to expand #immunotherapy efficacy in cancer ? Nature Reviews Drug Discovery nature.com/articles/s4157…

cell.com/cell/fulltext/…

Tumor suppression of novel anti–PD-1 antibodies mediated through CD28 costimulatory pathway jem.rupress.org/content/early/…

pubs.acs.org/doi/10.1021/ac…

jimmunol.org/content/202/10…

An innate-like Vδ1 γδ T cell compartment in the human breast is associated with remission in triple-negative breast cancer stm.sciencemag.org/content/11/513…

Emerging treatment options for the management of pemphigus vulgaris ncbi.nlm.nih.gov/pmc/articles/P…

Another paper on TCF1+ exhausted cells for I/O. Something new, something old. DOI:doi.org/10.1016/j.immu…

BTK in macrophages real? Bruton Tyrosine Kinase–Dependent Immune Cell Cross-talk Drives Pancreas Cancer cancerdiscovery.aacrjournals.org/content/6/3/270

Comparison of interleukin-2-inducible kinase (ITK) inhibitors and potential for combination therapies for T-cell… disq.us/t/36jumxg

Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against… disq.us/t/3idqm2p

Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy disq.us/t/3kbqn1i

An intra-tumoral niche maintains and differentiates stem-like CD8 T cells disq.us/t/3kbqu53

Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway ... sciencedirect.com/science/articl…

Tertiary lymphoid structures in the era of cancer immunotherapy rdcu.be/bZOWi

Targeted deletion of PD-1 in myeloid cells induces antitumor immunity immunology.sciencemag.org/content/5/43/e…

A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies stm.sciencemag.org/content/12/525…

nice summary of current IO therapies, Fig 3. rdcu.be/b0mHu

frontiersin.org/articles/10.33… T cells in sarcoidosis